Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363659 · ClinicalTrials.gov registry record · Phase 2
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03363659 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 15 participants.
The verdict
NCT03363659, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper. This study evaluates the impact of Disulfiram (DSF) + Copper (Cu) combination when added to standard Temozolomide in the treatment of unmethylated Glioblastoma Multiforme (GBM) patients.
Interventions
- DRUG Temozolomide
- DRUG Disulfiram
- DIETARY_SUPPLEMENT Copper gluconate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2022-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03363659
The ClinicalTrials.gov registry entry for NCT03363659 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT03363659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03363659 about?
NCT03363659 is a clinical study titled "Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme". One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper. This study evaluates the impact of Disulfiram (DSF) + Copper (Cu) combination when added to standard Temoz...
What is the current status of trial NCT03363659?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-03-28. Estimated completion is 2022-01-13.
What interventions are being tested in trial NCT03363659?
The interventions under investigation include: Temozolomide (DRUG), Disulfiram (DRUG), Copper gluconate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03363659?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.